Skip to main content

Table 1 Patient characteristics of the microarray cohort (n = 36 GBMs) and the validation cohort (n = 142 IDH1 wt GBMs), presented by location-dependent groups I–IV

From: Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone

Group I II III IV Total p value
Microarray cohort
 Patients, n (%) 11 (30) 6 (17) 10 (28) 9 (25) 36  
 Sex, n (male : female) 5 : 6 6 : 0 7 : 3 5 : 4 23 : 13 0.14a
 Age at diagnosis, mean (years) 68 64 59 64 65 0.21b
 Extent of resection, n (%)       0.85a
  - Complete 3 (27) 2 (33) 4 (40) 2 (22) 11 (31)  
  - Partial 4 (36.5) 4 (67) 5 (50) 5 (56) 18 (50)  
  - Unknown 4 (36.5) 0 1 (10) 2 (22) 7 (19)  
 OS, median (months) 9 9.5 15 16 11.5 0.98c
 PFS, median (months) 3 5.5 3 5 3.5 0.47c
 Multifocal CE lesion, n (%) 2 (18) 0 (0) 1 (10) 0 (0) 3 (8) 0.42a
 Multifocal FLAIR lesion, n (%) 2 (18) 0 (0) 3 (30) 0 (0) 5 (14) 0.19a
 MGMT promoter methylation, n (%)       0.06a
  - Yes 9 (82) 1 (17) 6 (60) 4 (44) 20 (56)  
  - No 2 (18) 5 (83) 4 (40) 5 (56) 16 (44)  
IDH1 mutation, n (%)       0.44a
  - Yes 0 0 1 (10) 0 1 (3)  
  - No 11 (100) 6 (100) 9 (90) 9 (100) 35 (97)  
Validation cohort
 Patients, n (%) 49 (35) 17 (12) 66 (46) 10 (7) 142  
 Sex, n (male : female) 31 : 18 9 : 8 41 : 25 6 : 4 87 : 55 0.89a
 Age at diagnosis, mean (years) 62 57 62 64 62 0.32d
 KPS preoperative, mean 78 76 86 86 82 0.01 d
 Extent of resection, n (%)       0.006 a
  - Complete 8 (16) 6 (35) 23 (35) 7 (70) 44 (31)  
  - Partial 37 (76) 9 (53) 31 (47) 2 (20) 79 (56)  
  - Unknown 4 (8) 2 (12) 12 (18) 1 (10) 19 (13)  
 Radiation therapy, n (%) 43 (88) 16 (94) 62 (94) 8 (80) 129 (91) 0.4a
 Temozolomide, n (%) 30 (61) 14 (82) 43 (65) 8 (80) 95 (67) 0.33a
 OS, median (months) 12 14 15 17 13 0.004 c
 PFS, median (months) 6 8 7 8 7 0.27c
 Censored patients, n (%) 2 (4) 1 (6) 4 (6) 0 (0) 7 (5) 0.85a
 MGMT promoter methylation       0.43a
  - Yes, n (%) 10 (20) 7 (41) 17 (26) 4 (40) 38 (26)  
  - No, n (%) 16 (33) 6 (35) 27 (41) 3 (30) 52 (37)  
  - Unknown, n (%) 23 (47) 4 (24) 22 (33) 3 (30) 52 (37)  
IDH1 mutation, n (%)       N/A
  - No, n (%) 49 (100) 17 (100) 66 (100) 10 (100) 142(100)  
  1. OS overall survival, PFS progression-free survival, CE contrast-enhancing, FLAIR fluid attenuated inversion recovery, MGMT O6-methylguanine-DNA methyltransferase, IDH1 isocitrate dehydrogenase 1, KPS Karnofsky performance score
  2. aChi-square test
  3. bKruskal-Wallis test
  4. cLog-rank test
  5. dOne-way ANOVA
  6. N/A not applicable
  7. In bold: p < 0.01